哮喘和ABPA患者血清蛋白生物标志物的筛选

Q4 Engineering Shenzhen Daxue Xuebao (Ligong Ban)/Journal of Shenzhen University Science and Engineering Pub Date : 2022-09-01 DOI:10.3724/sp.j.1249.2022.05538

Lei Yang, Yun Wang, M. Jin, Diquan Shuai, H. Cai, L. Ye, Shuiming Li, B. Shen

{"title":"哮喘和ABPA患者血清蛋白生物标志物的筛选","authors":"Lei Yang, Yun Wang, M. Jin, Diquan Shuai, H. Cai, L. Ye, Shuiming Li, B. Shen","doi":"10.3724/sp.j.1249.2022.05538","DOIUrl":null,"url":null,"abstract":"似,极易造成因漏诊、误诊而延误治疗.为提高这两种疾病诊断的准确性,运用蛋白芯片技术,分别检测哮喘患者、ABPA患者和正常对照受试者的血清蛋白质;经过生物信息软件分析,筛选出具有诊断价值的候选蛋白质生物标志物;利用多反应监测(multiple reaction monitoring,MRM)质谱和酶联免疫吸附测定法 (enzyme linked immunosorbent assay,ELISA),对候选靶标进行单一样本扩大数量和验证;并采用受试者工作特征(receiver operating characteristic,ROC)曲线,评估候选蛋白质生物标志物的诊断价值.研究发现:与正常对照组比较,哮喘组有7个差异表达蛋白质,ABPA组有15个差异表达蛋白质;与哮喘组比较,ABPA 组有 15个差异表达的蛋白质.MRM法的验证结果显示:与正常对照组比较,哮喘组的 SERPINF2、C6和 HABP2蛋白呈现显著性差异表达,ABPA组的SERPINF2和F10呈现显著性差异表达;ABPA组与哮喘组比较,CPN2和 IGLL5呈现显著性差异表达.ELISA法验证结果表明:ABPA患者血清的CSF1蛋白质水平明显低于哮喘患者的,而TNFRSF10C蛋白质水平明显高于哮喘患者的.ROC曲线结果显示:与正常对照组比较,哮喘组差异蛋白质C6的ROC曲线下面积(area under curve,AUC)为 0. 914,敏感度为 73. 3%,特异性为 99. 9%,ABPA组 F10的ROC曲线AUC为 0. 871,敏感度为 80. 0%,特异性为 85. 7%;与哮喘组比较, ABPA组中CPN2和 IGLL5联合诊断的AUC为0. 867,敏感度为86. 7%,特异性为80. 0%.由此可见,新筛选出的蛋白质生物标志物与哮喘或ABPA的发生发展密切相关,具有诊断与鉴别诊断的潜能.","PeriodicalId":35396,"journal":{"name":"Shenzhen Daxue Xuebao (Ligong Ban)/Journal of Shenzhen University Science and Engineering","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Screening out serum protein biomarkers from both groups of asthma and ABPA patients\",\"authors\":\"Lei Yang, Yun Wang, M. Jin, Diquan Shuai, H. Cai, L. Ye, Shuiming Li, B. Shen\",\"doi\":\"10.3724/sp.j.1249.2022.05538\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"似,极易造成因漏诊、误诊而延误治疗.为提高这两种疾病诊断的准确性,运用蛋白芯片技术,分别检测哮喘患者、ABPA患者和正常对照受试者的血清蛋白质;经过生物信息软件分析,筛选出具有诊断价值的候选蛋白质生物标志物;利用多反应监测(multiple reaction monitoring,MRM)质谱和酶联免疫吸附测定法 (enzyme linked immunosorbent assay,ELISA),对候选靶标进行单一样本扩大数量和验证;并采用受试者工作特征(receiver operating characteristic,ROC)曲线,评估候选蛋白质生物标志物的诊断价值.研究发现:与正常对照组比较,哮喘组有7个差异表达蛋白质,ABPA组有15个差异表达蛋白质;与哮喘组比较,ABPA 组有 15个差异表达的蛋白质.MRM法的验证结果显示:与正常对照组比较,哮喘组的 SERPINF2、C6和 HABP2蛋白呈现显著性差异表达,ABPA组的SERPINF2和F10呈现显著性差异表达;ABPA组与哮喘组比较,CPN2和 IGLL5呈现显著性差异表达.ELISA法验证结果表明:ABPA患者血清的CSF1蛋白质水平明显低于哮喘患者的,而TNFRSF10C蛋白质水平明显高于哮喘患者的.ROC曲线结果显示:与正常对照组比较,哮喘组差异蛋白质C6的ROC曲线下面积(area under curve,AUC)为 0. 914,敏感度为 73. 3%,特异性为 99. 9%,ABPA组 F10的ROC曲线AUC为 0. 871,敏感度为 80. 0%,特异性为 85. 7%;与哮喘组比较, ABPA组中CPN2和 IGLL5联合诊断的AUC为0. 867,敏感度为86. 7%,特异性为80. 0%.由此可见,新筛选出的蛋白质生物标志物与哮喘或ABPA的发生发展密切相关,具有诊断与鉴别诊断的潜能.\",\"PeriodicalId\":35396,\"journal\":{\"name\":\"Shenzhen Daxue Xuebao (Ligong Ban)/Journal of Shenzhen University Science and Engineering\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Shenzhen Daxue Xuebao (Ligong Ban)/Journal of Shenzhen University Science and Engineering\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3724/sp.j.1249.2022.05538\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Engineering\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Shenzhen Daxue Xuebao (Ligong Ban)/Journal of Shenzhen University Science and Engineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3724/sp.j.1249.2022.05538","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Engineering","Score":null,"Total":0}

引用次数: 0

摘要

Similarly, it is highly likely to cause delayed treatment due to missed diagnosis and misdiagnosis. To improve the accuracy of the diagnosis of these two diseases, protein chip technology is used to detect serum proteins in asthma patients, ABPA patients, and normal control subjects; After analysis by bioinformatics software, candidate protein biomarkers with diagnostic value were selected; Utilizing multiple reaction monitoring (MRM) mass spectrometry and enzyme linked immunosorbent assay (ELISA) to expand the number of single samples and validate candidate targets; And the receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of candidate protein biomarkers. The study found that compared with the normal control group, there were 7 differentially expressed proteins in the asthma group and 15 differentially expressed proteins in the ABPA group; Compared with the asthma group, the ABPA group had 15 differentially expressed proteins The validation results of the MRM method showed that compared with the normal control group, SERPINF2, C6, and HABP2 proteins in the asthma group showed significant differential expression, while SERPINF2 and F10 proteins in the ABPA group showed significant differential expression; Compared with the asthma group, the ABPA group showed significant differences in the expression of CPN2 and IGLL5 The ELISA validation results showed that the serum CSF1 protein levels in ABPA patients were significantly lower than those in asthma patients, while the TNFRSF10C protein levels were significantly higher than those in asthma patients The ROC curve results showed that compared with the normal control group, the area under curve (AUC) of the differential protein C6 in the asthma group was 0 914 with a sensitivity of 73 3%, with a specificity of 99 9%, the ROC curve AUC of ABPA group F10 is 0 871 with a sensitivity of 80 0%, specificity is 85 7%; Compared with the asthma group, the AUC for the combined diagnosis of CPN2 and IGLL5 in the ABPA group was 0 867, sensitivity 86.7%, specificity 80 0%. It can be seen that the newly screened protein biomarkers are closely related to the occurrence and development of asthma or ABPA, and have the potential for diagnosis and differential diagnosis

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Screening out serum protein biomarkers from both groups of asthma and ABPA patients

似,极易造成因漏诊、误诊而延误治疗.为提高这两种疾病诊断的准确性,运用蛋白芯片技术,分别检测哮喘患者、ABPA患者和正常对照受试者的血清蛋白质;经过生物信息软件分析,筛选出具有诊断价值的候选蛋白质生物标志物;利用多反应监测(multiple reaction monitoring,MRM)质谱和酶联免疫吸附测定法 (enzyme linked immunosorbent assay,ELISA),对候选靶标进行单一样本扩大数量和验证;并采用受试者工作特征(receiver operating characteristic,ROC)曲线,评估候选蛋白质生物标志物的诊断价值.研究发现:与正常对照组比较,哮喘组有7个差异表达蛋白质,ABPA组有15个差异表达蛋白质;与哮喘组比较,ABPA 组有 15个差异表达的蛋白质.MRM法的验证结果显示:与正常对照组比较,哮喘组的 SERPINF2、C6和 HABP2蛋白呈现显著性差异表达,ABPA组的SERPINF2和F10呈现显著性差异表达;ABPA组与哮喘组比较,CPN2和 IGLL5呈现显著性差异表达.ELISA法验证结果表明:ABPA患者血清的CSF1蛋白质水平明显低于哮喘患者的,而TNFRSF10C蛋白质水平明显高于哮喘患者的.ROC曲线结果显示:与正常对照组比较,哮喘组差异蛋白质C6的ROC曲线下面积(area under curve,AUC)为 0. 914,敏感度为 73. 3%,特异性为 99. 9%,ABPA组 F10的ROC曲线AUC为 0. 871,敏感度为 80. 0%,特异性为 85. 7%;与哮喘组比较, ABPA组中CPN2和 IGLL5联合诊断的AUC为0. 867,敏感度为86. 7%,特异性为80. 0%.由此可见,新筛选出的蛋白质生物标志物与哮喘或ABPA的发生发展密切相关,具有诊断与鉴别诊断的潜能.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Shenzhen Daxue Xuebao (Ligong Ban)/Journal of Shenzhen University Science and Engineering Engineering-Engineering (miscellaneous)

CiteScore

0.90

自引率

0.00%

发文量